Financial statements Notes to the consolidated financial statements continued 16.
Investments in associates and joint ventures The Groups share in Hubei Haosun Pharmaceutical Co Ltd China is 30.1% at 31 December 2016 31 December 2015: 30.1% with an investment balance of $4 million at 31 December 2016 31 December 2015: $4 million, The Groups share of the results of Hubei Haosun Pharmaceutical Co. Ltd is $nil 2015: share of the results of Unimark Remedies Limited and Hubei Haosun Pharmaceutical Co Ltd is a loss of $2million.
In previous periods, the Group impaired the remaining investment balance related to Unimark Remedies Limited of $7 million which was due to the continuous financial difficulties.
Hikmas share in Unimark Remedies Limited has been divested during 2016 for minimal value.
The below represents the Groups share of the result of Hikma Cure and Hubei Haosun Pharmaceutical Co Ltd. which is included in the consolidated income statement.
For the year ended 31 December 2016 For the year ended 31 December 2015 Joint Joint ventures Associates Total ventures Associates Total $m $m $m $m $m $m Balance at 1 January 3 4 7 3 13 16 Share of loss 2 2 Impairment of investment note 5 7 7 Balance at 31 December 3 4 7 3 4 7 Summarised financial information in respect of the Groups interests in associated companies is set out below: As at As at 31 December 31 December 2016 2015 $m $m Total assets 15 214 Total liabilities 5 160 Net assets 10 54 Groups share of net assets of associates 3 13 For the For the year ended year ended 31 December 31 December 2016 2015 $m $m Total revenue 4 49 Net loss 23 Groups share of loss of associates 2 17.
Deferred tax Certain deferred tax assets and liabilities have been appropriately offset.
The following is the analysis of the deferred tax balances after offset for financial reporting purposes: As at 31 December 2015 2016 $m $m Deferred tax liabilities 15 21 Deferred tax assets 172 70 157 49 Hikma Pharmaceuticals PLC 176 168 Hikma Pharmaceuticals plc
